Compare TECH & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TECH | IBRX |
|---|---|---|
| Founded | 1976 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.2B | 8.4B |
| IPO Year | 1995 | 2015 |
| Metric | TECH | IBRX |
|---|---|---|
| Price | $53.50 | $6.77 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 7 |
| Target Price | ★ $71.82 | $12.57 |
| AVG Volume (30 Days) | 2.0M | ★ 22.1M |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | ★ 0.59% | N/A |
| EPS Growth | N/A | ★ 38.71 |
| EPS | ★ 0.49 | N/A |
| Revenue | ★ $1,219,635,000.00 | $113,288,000.00 |
| Revenue This Year | $2.49 | $88.59 |
| Revenue Next Year | $6.40 | $131.15 |
| P/E Ratio | $109.85 | ★ N/A |
| Revenue Growth | 5.23 | ★ 668.31 |
| 52 Week Low | $46.02 | $1.83 |
| 52 Week High | $72.16 | $12.43 |
| Indicator | TECH | IBRX |
|---|---|---|
| Relative Strength Index (RSI) | 49.33 | 43.16 |
| Support Level | $49.48 | $6.54 |
| Resistance Level | $58.88 | $8.28 |
| Average True Range (ATR) | 1.98 | 0.88 |
| MACD | 0.62 | -0.19 |
| Stochastic Oscillator | 81.67 | 9.00 |
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.